- Conditions
- Cytomegalovirus (CMV) Infection
- Interventions
- Letermovir oral granules, Letermovir tablet, Letermovir intravenous
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Duarte, California • Orange, California • San Francisco, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2473–2496
of 17,851
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
- Interventions
- NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion
- Drug
- Lead sponsor
- TyrNovo Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Encinitas, California • Los Angeles, California • San Diego, California + 4 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Astegolimab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Jasper, Alabama + 56 more
- Conditions
- HIV Infections, Electronic Health Record, Primary Health Care
- Interventions
- EMC2 PrEP Educational Tool, Discrete Scheduling of a Dedicated PrEP Visit
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Solid Tumors
- Interventions
- ABBV-155, Paclitaxel, Docetaxel
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Orange, California + 17 more
- Conditions
- Alopecia Areata
- Interventions
- CTP-543
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
- Conditions
- HIV Infections, HIV Wasting Syndrome
- Interventions
- Testosterone enanthate, Megestrol acetate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2002
- U.S. locations
- 21
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 7
- States / cities
- Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
- Conditions
- Diabetes Mellitus II
- Interventions
- Muraglitazar
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 149
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 146 more
- Conditions
- Opioid-Induced Constipation
- Interventions
- Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 77
- States / cities
- Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more
- Conditions
- Cancer, Breakthrough Pain
- Interventions
- ACTIQ®
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 3 Years to 15 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 25 more
- Conditions
- HIV Infections
- Interventions
- maraviroc
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 1,047 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 190
- States / cities
- Birmingham, Alabama • Hobson City, Alabama • Tucson, Arizona + 113 more
- Conditions
- Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Interventions
- Stenoparib/Temozolomide, Lurbinectedin
- Combination Product · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Chicago, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- Non-Muscle Invasive Bladder Cancer
- Interventions
- Sacituzumab tirumotecan, Rescue medication, Supportive care measures
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Tampa, Florida • Chicago, Illinois + 1 more
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
- Interventions
- CNSide
- Device
- Lead sponsor
- Biocept, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Stanford, California • Chicago, Illinois • Dallas, Texas + 1 more
- Conditions
- Augmented Renal Clearance (ARC), Systemic Inflammatory Response Syndrome (SIRS)
- Interventions
- Ceftaroline fosamil/Avibactam (CXL)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 19
- States / cities
- Fresno, California • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Heart Disease, Ischemic, Atherosclerosis, Coronary
- Interventions
- Gadolinium, Adenosine
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Non-squamous Non-Small Cell Lung Cancer
- Interventions
- Pemetrexed, Carboplatin, Bevacizumab 7.5 mg/kg, Bevacizumab 15 mg/kg
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Evanston, Illinois • Harvey, Illinois
- Conditions
- Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Interventions
- cilengitide, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 19
- States / cities
- Oakland, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 858 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 83 more
- Conditions
- Parkinson's Disease
- Interventions
- Cycling at Forced rate, Cycling at self-selected rate
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Asthma
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- Facet Biotech
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 18
- States / cities
- Long Beach, California • Mission Viejo, California • San Diego, California + 14 more
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Interventions
- TransCon PTH, Placebo
- Combination Product
- Lead sponsor
- Ascendis Pharma Bone Diseases A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more
- Conditions
- Kidney Transplantation
- Interventions
- basiliximab, rabbit anti-thymocyte globulin, tacrolimus, alemtuzumab, mycophenolate mofetil, steroids
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 22 more